Publications:  Dr Andrea Malaspina

Sproviero W, Shatunov A, Stahl D, Shoai M, van Rheenen W, Jones AR, Al-Sarraj S, Andersen PM et al.(2916). ATXN2 trinucleotide repeat length correlates with risk of ALS. Neurobiol Aging vol. 51, Article e1-178.e9, 178.e1-178.e9.

Lombardi V, Carassiti D, Giovannoni G, Lu CH, Adiutori R, Malaspina A(2020). Author Correction: The potential of neurofilaments analysis using dry-blood and plasma spots (Scientific Reports, (2020), 10, 1, (97), 10.1038/s41598-019-54310-y). Scientific Reports vol. 10, (1)

Lombardi V, Carassiti D, Giovannoni G, Lu CH, Adiutori R, Malaspina A(2020). The potential of neurofilaments analysis using dry-blood and plasma spots. Scientific Reports vol. 10, (1)

Lombardi V, Bombaci A, Zampedri L, Lu C-H, Malik B, Zetterberg H, Heslegrave AJ, Rinaldi C et al.(2020). Plasma pNfH levels differentiate SBMA from ALS. J Neurol Neurosurg Psychiatry vol. 91, (2) 215-217.

Leoni E, Bremang M, Mitra V, Zubiri I, Jung S, Lu CH, Adiutori R, Lombardi V et al.(2019). Combined Tissue-Fluid Proteomics to Unravel Phenotypic Variability in Amyotrophic Lateral Sclerosis. Scientific Reports vol. 9, (1)

Wagley S, Bokori-Brown M, Morcrette H, Malaspina A, D'Arcy C, Gnanapavan S, Lewis N, Popoff MR et al.(2019). Evidence of Clostridium perfringens epsilon toxin associated with multiple sclerosis. Mult Scler vol. 25, (5) 653-660.

Lombardi V, Querin G, Ziff OJ, Zampedri L, Martinelli I, Heller C, Foiani M, Bertolin C et al.(2019). Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy. Neurology vol. 92, (11) E1205-E1211.

Gkiouleka A, Manning A, Smith D, Malaspina A, Gallo V(2019). Charity financial support to motor neuron disease (MND) patients in Greater London: the impact of patients' socioeconomic status-a cross-sectional study. BMJ Open vol. 9, (2)

Zubiri I, Lombardi V, Bremang M, Mitra V, Nardo G, Adiutori R, Lu CH, Leoni E et al.(2018). Tissue-enhanced plasma proteomic analysis for disease stratification in amyotrophic lateral sclerosis. Molecular Neurodegeneration vol. 13, (1)

Zucchi E, Lu CH, Cho Y, Chang R, Adiutori R, Zubiri I, Ceroni M, Cereda C et al.(2018). A motor neuron strategy to save time and energy in neurodegeneration: adaptive protein stoichiometry. Journal of Neurochemistry vol. 146, (5) 631-641.

Yildiz O, Mao Z, Adams A, Dubuisson N, Allen-Philbey K, Giovannoni G, Malaspina A, Baker D et al.(2018). Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine. Multiple Sclerosis and Related Disorders vol. 24, 20-27.

Conlon EG, Fagegaltier D, Agius P, Davis-Porada J, Gregory J, Hubbard I, Kang K, Kim D et al.(2018). Unexpected similarities between C9ORF72 and sporadic forms of ALS/FTD suggest a common disease mechanism. eLife vol. 7,

Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A(2018). Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Annals of Neurology vol. 84, (1) 130-139.

Adiutori R, Aarum J, Zubiri I, Bremang M, Jung S, Sheer D, Pike I, Malaspina A(2018). The proteome of neurofilament-containing protein aggregates in blood. Biochemistry and Biophysics Reports vol. 14, 168-177.

Keddie S, Adams A, Kelso ARC, Turner B, Schmierer K, Gnanapavan S, Malaspina A, Giovannoni G et al.(2018). No laughing matter: subacute degeneration of the spinal cord due to nitrous oxide inhalation. Journal of Neurology vol. 265, (5) 1089-1095.

Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, Dominov JA, Kenna BJ et al.(2018). Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron vol. 97, (6) 1268-1283.e6.

Rossor AM, Sandelius A, Adiutori R, Malaspina A, Blennow K, Zetterberg H, Reilly MM (2018). PLASMA NEUROFILAMENT LIGHT CHAIN LEVELS ARE RAISED IN PATIENTS WITH INHERITED PERIPHERAL NEUROPATHY AND CORRELATE WITH DISEASE SEVERITY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. Conference: 11th UK Neuromuscular Translational Research Conference from: 20/04/2018 to: 18/04/2018, vol. 22, 369-370.

Sandelius Å, Zetterberg H, Blennow K, Adiutori R, Malaspina A, Laura M, Reilly MM, Rossor AM(2018). Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology vol. 90, (6) e518-e524.

Gallo V, McElvenny D, Hobbs C, Davoren D, Morris H, Crutch S, Zetterberg H, Fox NC et al.(2017). BRain health and healthy AgeINg in retired rugby union players, the BRAIN Study: study protocol for an observational study in the UK. BMJ Open vol. 7, (12) Article e017990, e017990-e017990.

Morgan S, Shatunov A, Sproviero W, Jones AR, Shoai M, Hughes D, Al Khleifat A, Malaspina A et al.(2017). A comprehensive analysis of rare genetic variation in amyotrophic lateral sclerosis in the UK. Brain vol. 140, (6) 1611-1618.

McLaughlin RL, Schijven D, Van Rheenen W, Van Eijk KR, O'Brien M, Kahn RS, Ophoff RA, Goris A et al.(2017). Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. Nature Communications vol. 8,

Rossor AM, Lu C-H, Petzold A, Malaspina A, Laura M, Greensmith L, Reilly MM(2016). Plasma neurofilament heavy chain is not a useful biomarker in Charcot-Marie-Tooth disease (vol 53, pg 972, 2016). MUSCLE & NERVE vol. 55, (1) 141-141.

Van Rheenen W, Shatunov A, Dekker AM, McLaughlin RL, Diekstra FP, Pulit SL, Van Der Spek RAA, Võsa U et al.(2016). Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nature Genetics vol. 48, (9) 1043-1048.

McGeachan AJ, Hobson EV, Al-Chalabi A, Stephenson J, Chandran S, Crawley F, Dick D, Donaghy C et al.(2016). A multicentre evaluation of oropharyngeal secretion management practices in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration vol. 18, (1-2) 1-9.

Rossor AM, Liu C-H, Petzold A, Malaspina A, Laura M, Greensmith L, Reilly MM(2016). PLASMA NEUROFILAMENT HEAVY CHAIN IS NOT A USEFUL BIOMARKER IN CHARCOT-MARIE-TOOTH DISEASE. MUSCLE & NERVE vol. 53, (6) 972-975.

Rossor AM, Liu CH, Petzold A, Malaspina A, Laura M, Greensmith L, Reilly MM (2016). Plasma neurofilament heavy chain is not a useful biomarker in Charcot-Marie-Tooth disease. Muscle and Nerve. vol. 53, 972-975.

Lu C-H, Allen K, Oei F, Leoni E, Kuhle J, Tree T, Fratta P, Sharma N et al.(2016). Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurology - Neuroimmunology Neuroinflammation vol. 3, (4) e244-e244.

Puentes F, Malaspina A, Van Noort JM, Amor S(2016). Non-neuronal cells in ALS: Role of glial, immune cells and blood-CNS barriers. Brain Pathology vol. 26, (2) 248-257.

Abdelkarim S, Morgan S, Plagnol V, Lu CH, Adamson G, Howard R, Malaspina A, Orrell R et al.(2016). CHCHD10 Pro34Ser is not a highly penetrant pathogenic variant for amyotrophic lateral sclerosis and frontotemporal dementia. Brain vol. 139, (2)

(2015). Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology vol. 85, (10) 921.2-921.

Menke RAL, Gray E, Lu CH, Kuhle J, Talbot K, Malaspina A, Turner MR(2015). CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Annals of Clinical and Translational Neurology vol. 2, (7) 748-755.

ProGas Study Group(2015). Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study. Lancet Neurol vol. 14, (7) 702-709.

Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, Giovannoni G, Fratta P et al.(2015). Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology vol. 84, (22) 2247-2257.

Lu C-H, Petzold A, Topping J, Allen K, Macdonald-Wallis C, Clarke J, Pearce N, Kuhle J et al.(2015). Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. J Neurol Neurosurg Psychiatry vol. 86, (5) 565-573.

Pettingill P, Kramer HB, Coebergh JA, Pettingill R, Maxwell S, Nibber A, Malaspina A, Jacob A et al.(2015). Antibodies to GABAA receptor α1 and γ2 subunits: clinical and serologic characterization. Neurology vol. 84, (12) 1233-1241.

Malaspina A, Puentes F, Amor S(2015). Disease origin and progression in amyotrophic lateral sclerosis: an immunology perspective. Int Immunol vol. 27, (3) 117-129.

Morgan S, Shoai M, Fratta P, Sidle K, Orrell R, Sweeney MG, Shatunov A, Sproviero W et al.(2015). Investigation of next-generation sequencing technologies as a diagnostic tool for amyotrophic lateral sclerosis. Neurobiology of Aging vol. 36, (3) 1600.e5-1600.e8.

Kuhle J, Gaiottino J, Leppert D, Petzold A, Bestwick JP, Malaspina A, Lu C-H, Dobson R et al.(2015). Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. J Neurol Neurosurg Psychiatry vol. 86, (3) 273-279.

Fratta P, Polke JM, Newcombe J, Mizielinska S, Lashley T, Poulter M, Beck J, Preza E et al.(2015). Screening a UK amyotrophic lateral sclerosis cohort provides evidence of multiple origins of the C9orf72 expansion. Neurobiol Aging vol. 36, (1) 546.e1-546.e7.

Amor S, van der Star BJ, Bosca I, Raffel J, Gnanapavan S, Watchorn J, Kuhle J, Giovannoni G et al.(2014). Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis. Mult Scler vol. 20, (10) 1355-1362.

Fratta P, Nirmalananthan N, Masset L, Skorupinska I, Collins T, Cortese A, Pemble S, Malaspina A et al.(2014). Correlation of clinical and molecular features in spinal bulbar muscular atrophy. Neurology vol. 82, (23) 2077-2084.

Johnson JO, Pioro EP, Boehringer A, Chia R, Feit H, Renton AE, Pliner HA, Abramzon Y et al.(2014). Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat Neurosci vol. 17, (5) 664-666.

Fratta P, Charnock J, Collins T, Devoy A, Howard R, Malaspina A, Orrell R, Sidle K et al.(2014). Profilin1 E117G is a moderate risk factor for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry vol. 85, (5) 506-508.

Puentes F, Topping J, Kuhle J, van der Star BJ, Douiri A, Giovannoni G, Baker D, Amor S et al.(2014). Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry vol. 85, (3) 274-278.

Hobson EV, McGeachan A, Al-Chalabi A, Chandran S, Crawley F, Dick D, Donaghy C, Ealing J et al.(2013). Management of sialorrhoea in motor neuron disease: a survey of current UK practice. Amyotroph Lateral Scler Frontotemporal Degener vol. 14, (7-8) 521-527.

Kuhle J, Plattner K, Bestwick JP, Lindberg RL, Ramagopalan SV, Norgren N, Nissim A, Malaspina A et al.(2013). A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult Scler vol. 19, (12) 1597-1603.

Beck J, Poulter M, Hensman D, Rohrer JD, Mahoney CJ, Adamson G, Campbell T, Uphill J et al.(2013). Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am J Hum Genet vol. 92, (3) 345-353.

Cristante E, McArthur S, Mauro C, Maggioli E, Romero IA, Wylezinska-Arridge M, Couraud PO, Lopez-Tremoleda J et al.(2013). Identification of an essential endogenous regulator of blood-brain barrier integrity, and its pathological and therapeutic implications. Proc Natl Acad Sci U S A vol. 110, (3) 832-841.

Gaiottino J, Norgren N, Dobson R, Topping J, Nissim A, Malaspina A, Bestwick JP, Monsch AU et al.(2013). Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One vol. 8, (9)

Yip PK, Pizzasegola C, Gladman S, Biggio ML, Marino M, Jayasinghe M, Ullah F, Dyall SC et al.(2013). The omega-3 fatty acid eicosapentaenoic acid accelerates disease progression in a model of amyotrophic lateral sclerosis. PLoS One vol. 8, (4)

Lu CH, Petzold A, Kalmar B, Dick J, Malaspina A, Greensmith L(2012). Plasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1(G93A) mice that model ALS. PLoS One

Yip PK, Malaspina A(2012). Spinal cord trauma and the molecular point of no return. Mol Neurodegener vol. 7,

Lu C-H, Petzold A, Kalmar B, Dick J, Malaspina A, Greensmith L(2012). Plasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1(G93A) mice that model ALS. PLoS One vol. 7, (7)

Otto M, Bowser R, Turner M, Berry J, Brettschneider J, Connor J, Costa J, Cudkowicz M et al.(2012). Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph Lateral Scler vol. 13, (1) 1-10.

Lu C-H, Kalmar B, Malaspina A, Greensmith L, Petzold A(2011). A method to solubilise protein aggregates for immunoassay quantification which overcomes the neurofilament "hook" effect. J Neurosci Methods vol. 195, (2) 143-150.

LU C, Kalmar B, Malaspina A, Greensmith L, Petzold A(2010). A method to solubilise protein aggregates for immunoassay quantification which overcomes the neurofilament “hook” effect. J Neurosci Methods vol. 195, (2) 143-150.

Jokic N, Yip PK, Michael-Titus A, Priestley JV, Malaspina A(2010). The human G93A-SOD1 mutation in a pre-symptomatic rat model of amyotrophic lateral sclerosis increases the vulnerability to a mild spinal cord compression. BMC Genomics vol. 11,

Lu C, Malaspina A, Orrell R, Kalmar B, Petzold A, Greensmith L(2010). PONM06 Plasma neurofilament heavy chain levels as a disease biomarker in the SOD1 mouse model of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry vol. 81, (11)

Malaspina A, Ngoh SFA, Ward RE, Hall JCE, Tai FWD, Yip PK, Jones C, Jokic N et al.(2010). Activation transcription factor-3 activation and the development of spinal cord degeneration in a rat model of amyotrophic lateral sclerosis. Neuroscience vol. 169, (2) 812-827.

Malaspina A, Jokic N, Huang WL, Priestley JV(2008). Comparative analysis of the time-dependent functional and molecular changes in spinal cord degeneration induced by the G93A SOD1 gene mutation and by mechanical compression. BMC Genomics vol. 9,

Malaspina AC, Cavalcanti HR, Leite CQF, Machado SMA, Viana BHJ, Silva RMG, Hage EF, Figueiredo WM et al.(2008). Usefulness of Mycobacterium tuberculosis molecular typing in a tuberculosis low-endemic agro-industrial setting of Brazil. Jpn J Infect Dis vol. 61, (3) 231-233.

Malaspina A, Michael-Titus AT(2008). Is the modulation of retinoid and retinoid-associated signaling a future therapeutic strategy in neurological trauma and neurodegeneration?. J Neurochem vol. 104, (3) 584-595.

Jokic N, Ling YY, Ward RE, Michael-Titus AT, Priestley JV, Malaspina A(2007). Retinoid receptors in chronic degeneration of the spinal cord: observations in a rat model of amyotrophic lateral sclerosis. J Neurochem vol. 103, (5) 1821-1833.

Malaspina A, Turkheimer F(2007). A review of the functional role and of the expression profile of retinoid signaling and of nuclear receptors in human spinal cord. Brain Res Bull vol. 71, (5) 437-446.

Cereda C, Gabanti E, Corato M, de Silvestri A, Alimonti D, Cova E, Malaspina A, Ceroni M(2006). Increased incidence of FMO1 gene single nucleotide polymorphisms in sporadic amyotrophic lateral sclerosis. Amyotroph Lateral Scler vol. 7, (4) 227-234.

Malaspina A, de Belleroche J(2004). Spinal cord molecular profiling provides a better understanding of Amyotrophic Lateral Sclerosis pathogenesis. BRAIN RES REV vol. 45, (3) 213-229.

Malaspina A, de Belleroche J(2004). Spinal cord molecular profiling provides a better understanding of amyotrophic lateral sclerosis pathogenesis. Brain Res Brain Res Rev vol. 45, (3) 213-229.

Malaspina A, Pearce RKB, Graeber MB(2003). Nuclear hormone and orphan receptors: their role in neuronal differentiation and cytoprotection and in the pathogenesis of Parkinson's disease. Dev Neurosci vol. 25, (6) 375-383.

Malaspina A, Alimonti D, Poloni TE, Ceroni M(2002). Disease clustering: the example of ALS, PD, dementia and hereditary ataxias in Italy. Funct Neurol vol. 17, (4) 177-182.

Curti D, Rognoni F, Alimonti D, Malaspina A, Feletti F, Tessera S, Finotti N, Rehak L et al.(2002). SOD1 activity and protective factors in familial ALS patients with L84F SOD1 mutation. Amyotroph Lateral Scler Other Motor Neuron Disord vol. 3, (3) 115-122.

Malaspina A, Kaushik N, de Belleroche J (2001). A survey of trinucleotide/tandem repeat-containing transcripts (TNRTs) isolated from human spinal cord to identify genes containing unstable DNA regions as candidates for disorders of motor function. Brain Res Bull. vol. 56, 299-306.

Malaspina A, Kaushik N, de Belleroche J(2001). Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays. J Neurochem vol. 77, (1) 132-145.

Malaspina A, Kaushik N, de Belleroche J(2000). A 14-3-3 mRNA is up-regulated in amyotrophic lateral sclerosis spinal cord. J Neurochem vol. 75, (6) 2511-2520.

Alimonti D, Malaspina A, Poloni TE, Ceroni M(2000). Genotype-phenotype correlation in familial amyotrophic lateral sclerosis with SOD1 mutation. Funct Neurol vol. 15, (3) 177-191.

Ceroni M, Poloni TE, Tonietti S, Fabozzi D, Uggetti C, Frediani F, Simonetti F, Malaspina A et al.(2000). Migraine with aura and white matter abnormalities: Notch3 mutation. Neurology vol. 54, (9) 1869-1871.

Kaushik N, Malaspina A, de Belleroche J(2000). Characterization of trinucleotide- and tandem repeat-containing transcripts obtained from human spinal cord cDNA library by high-density filter hybridization. DNA Cell Biol vol. 19, (5) 265-273.

Mitchell J, Habgood JJ, Orrell RW, Kaushik N, Malaspina A, Gardiner IM, Greenwood JS, de Belleroche JS(2000). Identifying gene defects in motor neurone disease /amyotrophic lateral sclerosis families that lack Cu/Zn superoxide dismutase mutations. EUR J NEUROSCI vol. 12, 226-226.

Orrell RW, Habgood JJ, Malaspina A, Mitchell J, Greenwood J, Lane RJ, deBelleroche JS (1999). Clinical characteristics of SOD1 gene mutations in UK families with ALS. J Neurol Sci. vol. 169, 56-60.

Ceroni M, Malaspina A, Poloni TE, Alimonti D, Rognoni F, Habgood J, Imbesi F, Antonelli P et al.(1999). Clustering of ALS patients in central Italy due to the occurrence of the L84F SOD1 gene mutation. Neurology vol. 53, (5) 1064-1071.

Poloni TE, Alimonti D, Montagna G, Segagni S, Imbesi F, Malaspina A, Ceroni M(1999). Renal tubular impairment during riluzole therapy. Neurology vol. 52, (3)

Malaspina A, Zaman R, Mazzini L, Camana C, Poloni E, Curti D, Ceroni M(1999). Heterogeneous distribution of amyotrophic lateral sclerosis patients with SOD-1 gene mutations: preliminary data on an Italian survey. J Neurol Sci vol. 162, (2) 201-204.

de Belleroche J, Orrell RW, Virgo L, Habgood J, Gardiner IM, Malaspina A, Kaushik N, Mitchell J et al. (1998). Copper, zinc superoxide dismutase (SOD1) and its role in neuronal function and disease with particular relevance to motor neurone disease/amyotrophic lateral sclerosis. Biochem Soc Trans. vol. 26, 476-480.

Kaushik N, Malaspina A, Schalling M, Baas F, de Belleroche J(1998). Isolation and characterization of trinucleotide repeat containing partial transcripts in human spinal cord. Neurogenetics vol. 1, (4) 239-247.

Rognoni F, Malaspina A, Poloni E, Camana C, Facchini M, Giardini I, Cremona K, Rahak L et al.(1998). Different pathways of oxidative injury in sporadic and familial amyotrophic lateral sclerosis (ALS). EUR J NEUROSCI vol. 10, 374-374.

Curti D, Malaspina A, Facchetti G, Camana C, Mazzini L, Tosca P, Zerbi F, Ceroni M(1996). Amyotrophic lateral sclerosis: oxidative energy metabolism and calcium homeostasis in peripheral blood lymphocytes. Neurology vol. 47, (4) 1060-1064.

Marchioni E, Perucca E, Soragna D, Bo P, Malaspina A, Ferrandi D, Albergati A, Savoldi F(1996). Choreiform syndrome associated with fluoxetine treatment in a patient with deficient CYP2D6 activity. Neurology vol. 46, (3)

Sartore M, Grasso M, Piccolo G, Fasani R, Bergamaschi R, Malaspina A, Ceroni M, Kobayashi M et al.(1995). Leber's hereditary optic neuropathy (LHON)-related mitochondrial DNA sequence changes in italian patients presenting with sporadic bilateral optic neuritis. Biochem Mol Med vol. 56, (1) 45-51.

Sartore M, Grasso M, Piccolo G, Fasani R, Bergamaschi R, Ceroni M, MALASPINA A, Kobayashi M et al.(1995). Leber's hereditary optic neuropathy (LHON)-related mitochondrial DNA sequence changes in italian patients presenting with sporadic bilateral optic neuritis. Biochem Mol Med vol. 56, (1) 45-51.

MALASPINA A, Piccolo G, Arbustini E, Romani A, Bergamaschi R, Grasso M, Simonetti F, Lorusso L et al.(1994). A. Malaspina, G. Piccolo, E. Arbustini, A. Romani, R. Bergamaschi , M. Grasso, F. Simonetti, L. Lorusso, G. Giardini, F. Savoldi, M. Ceroni. Su un caso di neuropatia ottica retrobulbare bilaterale di difficile diagnosi: una malattia mitocondriale?. Riv. Neurobiologia vol. 40, 77-83.

Giardini G, Simonetti F, MALASPINA A, Lorusso L, Marchioni E, Marinu-Aktipi R, Barletta L, Zerbi D et al.(1994). Central Nervous System autoantibodies in neurologic paraneoplastic syndromes. Medecine Biologie Environnement vol. 22, 241-247.

Bolzani W, Montalbetti L, Barletta L, MALASPINA A, Uggetti C, Ceroni M, Savoldi F(1993). A case of parietal atrophy: etiopathogenetic evaluation. Acta Neurologica Scandinavica vol. 15, (6) 416-420.

Bolzani W, Montalbetti L, Barletta L, Malaspina A, Uggetti C, Ceroni M, Savoldi F(1993). A case of parietal atrophy: etiopathogenetic evaluation. Acta Neurol (Napoli) vol. 15, (6) 416-420.

Giardini G, Lorusso L, Barletta L, Malaspina A, Bolzani W, Savoldi F, Ceroni M(1993). Myelin basic protein purification in non denaturing conditions. Boll Soc Ital Biol Sper vol. 69, (10) 579-585.

Giardini G, Lorusso L, Barletta L, Bolzani W, MALASPINA A, Savoldi F, Ceroni M(1993). Myelin basic protein purification in non denaturing conditions. Boll Soc Ital Biol Sper. vol. 69, (10) 579-585.